Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial

NCT03455725 · View on ClinicalTrials.gov ↗

Study Summary

Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled, double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham treatment Treatment Group: Subjects treated with aBMC using the CardiAMP cell therapy system Sham Control Group: Subjects treated with a Sham Treatment (no introduction of the Helix transendocardial delivery catheter, no administration of aBMC)

Interventions

  • DEVICE CardiAMP Cell Therapy System
  • OTHER Sham Treatment

Study Locations (2)

Florida

  • University of Florida — Gainesville

Wisconsin

  • University of Wisconsin Madison — Madison

Trial Details

FieldValue
Enrollment Target 343 participants
Start Date 2021-06-30
Est. Completion 2027-12
Phase NA

Sponsor

BioCardia

3 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03455725

The ClinicalTrials.gov registry entry for NCT03455725 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 343 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCardia, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Refractory Angina appearing as the primary indexed condition, and to 2 interventions — of which CardiAMP Cell Therapy System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03455725 reports 2 study locations spanning 2 distinct geographic areas — top geographies include Florida, Wisconsin. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03455725 about?

NCT03455725 is a clinical study titled "CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial". Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled, double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham treatment Treatment Group: Subjects treated with aBMC using the CardiAMP cell therapy system Sham Control Group: Subject...

What is the current status of trial NCT03455725?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 343 participants. The study started on 2021-06-30. Estimated completion is 2027-12.

What conditions does trial NCT03455725 study?

This clinical trial studies the following conditions: Refractory Angina, Chronic Myocardial Ischemia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03455725?

The interventions under investigation include: CardiAMP Cell Therapy System (DEVICE), Sham Treatment (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03455725?

This trial is sponsored by BioCardia, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03455725 being conducted?

This trial has 2 study locations across Florida, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial